Management of Dapsone-Induced Pancytopenia
Immediate Actions
- The American Society of Clinical Oncology recommends immediate discontinuation of dapsone and initiation of supportive care with corticosteroids (prednisone 1-2 mg/kg/day) upon detection of pancytopenia 1
- Grade 3-4 pancytopenia requires hospital admission, and immediate hematology consultation is necessary for all cases of Grade 2 or higher 1
Diagnostic Workup
- Essential laboratory evaluation includes complete blood count with differential, peripheral smear for morphology, reticulocyte count, LDH, haptoglobin, bilirubin (direct and indirect), and free hemoglobin to assess for concurrent hemolysis 1
- The American Academy of Dermatology recommends checking G6PD level if not previously checked, especially in patients with a history of hemolysis 2
Pharmacologic Management
- The American Society of Clinical Oncology recommends prednisone 1-2 mg/kg/day orally or IV equivalent, depending on severity, and continuing until blood counts recover, then tapering gradually 1
Supportive Care
- The American Society of Clinical Oncology recommends RBC transfusion per existing guidelines, transfusing the minimum units necessary to relieve symptoms or achieve safe hemoglobin (7-8 g/dL in stable, non-cardiac inpatients) 1
- The British Association of Dermatologists recommends monitoring closely for respiratory, cardiovascular, and other infections 4
Long-Term Considerations
- Dapsone is permanently contraindicated after pancytopenia develops, and other sulfonamide-containing medications should be avoided due to cross-reactivity risk 1, 3
- The American Society of Hematology recommends considering alternative second-line agents, such as rituximab, thrombopoietin receptor agonists (romiplostim, eltrombopag), azathioprine, cyclosporine, or mycophenolate mofetil, for underlying conditions like chronic ITP 5, 6